Cargando…

Interactions of the protease inhibitor, ritonavir, with common anesthesia drugs

The protease inhibitor, ritonavir, is a strong inhibitor of CYP 3A. The drug is used for management of the human immunovirus and is currently part of an oral antiviral drug combination (nirmatrelvir–ritonavir) for the early treatment of SARS‐2 COVID‐19‐positive patients aged 12 years and over who ha...

Descripción completa

Detalles Bibliográficos
Autores principales: Svedmyr, Anders, Hack, Henrik, Anderson, Brian J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9543968/
https://www.ncbi.nlm.nih.gov/pubmed/35842922
http://dx.doi.org/10.1111/pan.14529
_version_ 1784804494983299072
author Svedmyr, Anders
Hack, Henrik
Anderson, Brian J.
author_facet Svedmyr, Anders
Hack, Henrik
Anderson, Brian J.
author_sort Svedmyr, Anders
collection PubMed
description The protease inhibitor, ritonavir, is a strong inhibitor of CYP 3A. The drug is used for management of the human immunovirus and is currently part of an oral antiviral drug combination (nirmatrelvir–ritonavir) for the early treatment of SARS‐2 COVID‐19‐positive patients aged 12 years and over who have recognized comorbidities. The CYP 3A enzyme system is responsible for clearance of numerous drugs used in anesthesia (e.g., alfentanil, fentanyl, methadone, rocuronium, bupivacaine, midazolam, ketamine). Ritonavir will have an impact on drug clearances that are dependent on ritonavir concentration, anesthesia drug intrinsic hepatic clearance, metabolic pathways, concentration‐response relationship, and route of administration. Drugs with a steep concentration‐response relationship (ketamine, midazolam, rocuronium) are mostly affected because small changes in concentration have major changes in effect response. An increase in midazolam concentration is observed after oral administration because CYP 3A in the gastrointestinal wall is inhibited, causing a large increase in relative bioavailability. Fentanyl infusion may be associated with a modest increase in plasma concentration and effect, but the large between subject variability of pharmacokinetic and pharmacodynamic concentration changes suggests it will have little impact on an individual patient, especially when used with adverse effect monitoring. It has been proposed that drugs that have no or only a small metabolic pathway involving the CYP 3A enzyme be used during anesthesia, for example, propofol, atracurium, remifentanil, and the volatile agents. That anesthesia approach denies children of drugs with considerable value. It is better that the inhibitory changes in clearance of these drugs are understood so that rational drug choices can be made to tailor drug use to the individual patient. Altered drug dose, anticipation of duration of effect, timing of administration, use of reversal agents and perioperative monitoring would better behoove children undergoing anesthesia.
format Online
Article
Text
id pubmed-9543968
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-95439682022-10-14 Interactions of the protease inhibitor, ritonavir, with common anesthesia drugs Svedmyr, Anders Hack, Henrik Anderson, Brian J. Paediatr Anaesth Educational Review The protease inhibitor, ritonavir, is a strong inhibitor of CYP 3A. The drug is used for management of the human immunovirus and is currently part of an oral antiviral drug combination (nirmatrelvir–ritonavir) for the early treatment of SARS‐2 COVID‐19‐positive patients aged 12 years and over who have recognized comorbidities. The CYP 3A enzyme system is responsible for clearance of numerous drugs used in anesthesia (e.g., alfentanil, fentanyl, methadone, rocuronium, bupivacaine, midazolam, ketamine). Ritonavir will have an impact on drug clearances that are dependent on ritonavir concentration, anesthesia drug intrinsic hepatic clearance, metabolic pathways, concentration‐response relationship, and route of administration. Drugs with a steep concentration‐response relationship (ketamine, midazolam, rocuronium) are mostly affected because small changes in concentration have major changes in effect response. An increase in midazolam concentration is observed after oral administration because CYP 3A in the gastrointestinal wall is inhibited, causing a large increase in relative bioavailability. Fentanyl infusion may be associated with a modest increase in plasma concentration and effect, but the large between subject variability of pharmacokinetic and pharmacodynamic concentration changes suggests it will have little impact on an individual patient, especially when used with adverse effect monitoring. It has been proposed that drugs that have no or only a small metabolic pathway involving the CYP 3A enzyme be used during anesthesia, for example, propofol, atracurium, remifentanil, and the volatile agents. That anesthesia approach denies children of drugs with considerable value. It is better that the inhibitory changes in clearance of these drugs are understood so that rational drug choices can be made to tailor drug use to the individual patient. Altered drug dose, anticipation of duration of effect, timing of administration, use of reversal agents and perioperative monitoring would better behoove children undergoing anesthesia. John Wiley and Sons Inc. 2022-07-24 2022-10 /pmc/articles/PMC9543968/ /pubmed/35842922 http://dx.doi.org/10.1111/pan.14529 Text en © 2022 The Authors. Pediatric Anesthesia published by John Wiley & Sons Ltd. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Educational Review
Svedmyr, Anders
Hack, Henrik
Anderson, Brian J.
Interactions of the protease inhibitor, ritonavir, with common anesthesia drugs
title Interactions of the protease inhibitor, ritonavir, with common anesthesia drugs
title_full Interactions of the protease inhibitor, ritonavir, with common anesthesia drugs
title_fullStr Interactions of the protease inhibitor, ritonavir, with common anesthesia drugs
title_full_unstemmed Interactions of the protease inhibitor, ritonavir, with common anesthesia drugs
title_short Interactions of the protease inhibitor, ritonavir, with common anesthesia drugs
title_sort interactions of the protease inhibitor, ritonavir, with common anesthesia drugs
topic Educational Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9543968/
https://www.ncbi.nlm.nih.gov/pubmed/35842922
http://dx.doi.org/10.1111/pan.14529
work_keys_str_mv AT svedmyranders interactionsoftheproteaseinhibitorritonavirwithcommonanesthesiadrugs
AT hackhenrik interactionsoftheproteaseinhibitorritonavirwithcommonanesthesiadrugs
AT andersonbrianj interactionsoftheproteaseinhibitorritonavirwithcommonanesthesiadrugs